These observations strongly supported the development of clinical trials aiming to evaluate the potential clinical benefit deriving from the treatment of IDH1/IDH2 mutant AML and MDS with clinically approved PARP inhibitors. The gene discussed is IDH2; the disease is acute myeloid leukemia.